OcuPro, a new device from Oculogica for testing impairment after cannabis use, was featured on Kare 11 News.
The device has gone through several design iterations already, according to Joel Sanderson, Oculogica’s chief technology officer. “We’re always exploring new technologies; improving ways to keep doing things better,” said Sanderson.…
Neuro-diagnostic company Oculogica today announced the launch of OcuPro, the fastest roadside cannabis test with immediate results, along with pilots planned with several police departments across the U.S. Officers administer the 45-second long test and receive an immediate indication of recent cannabis use and impairment.…
Cognition Therapeutics reported on 2nd quarter financial results and business updates including optimistic advancements in clinical trials.
Analytic results in a study of Cognition Therapeutic’s CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, indicates a reduction in the YKL-40, a biomarker for inflammation associated with Alzheimer’s.
DHS has selected Kenzen’s wearable technology that helps prevent heat related injuries for their SVIP program. The SVIP program identifies innovative technology that could protect employees and save lives. Read full press release here. …
Atlantic City, NJ (May 19, 2022) – Recognizing the most ingenious and innovative ideas recently financed by members of the Angel Capital Association, the prestigious Luis Villalobos Award was recently awarded to two companies disrupting their fields. Recognized were Healionics, a company making dialysis safer for those in kidney failure in the Life Sciences category, and Tilt, a company revolutionizing employee leave management in the workplace, in the Technology, Services and Consumer category.…
As our infrastructure continues to age, systems across the U.S. will continue to fail at an alarming rate without immediate intervention. Storm Sensor’s SURFR adds a new risk assessment tool to its line of flood mitigation hardware and software.
Kidizen partners with Tea Collection to provide platform for resale of kid’s clothing, the most rapidly growing segment of the resale marketplace.
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.…